X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33655) 33655
Newspaper Article (855) 855
Newsletter (718) 718
Book Chapter (260) 260
Magazine Article (76) 76
Transcript (13) 13
Dissertation (5) 5
Book / eBook (4) 4
Book Review (3) 3
Conference Proceeding (3) 3
Reference (3) 3
Web Resource (2) 2
Publication (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28173) 28173
female (14085) 14085
male (10841) 10841
middle aged (8969) 8969
antibodies, monoclonal, humanized (8879) 8879
oncology (8800) 8800
animals (7534) 7534
antibodies, monoclonal - therapeutic use (7526) 7526
adult (7389) 7389
aged (7106) 7106
treatment outcome (7052) 7052
antibodies, monoclonal - administration & dosage (6175) 6175
monoclonal antibodies (6166) 6166
bevacizumab (5842) 5842
antibodies, monoclonal, humanized - administration & dosage (5837) 5837
cancer (5468) 5468
antibodies, monoclonal, humanized - therapeutic use (5200) 5200
care and treatment (4408) 4408
antineoplastic combined chemotherapy protocols - therapeutic use (4352) 4352
immunology (4121) 4121
antibodies (4055) 4055
therapy (4048) 4048
chemotherapy (3965) 3965
monoclonal-antibody (3876) 3876
pharmacology & pharmacy (3801) 3801
mice (3646) 3646
antibodies, monoclonal - adverse effects (3509) 3509
research (3354) 3354
immunotherapy (3339) 3339
drug therapy (3329) 3329
medicine & public health (3040) 3040
clinical trials (2985) 2985
antibodies, monoclonal, humanized - adverse effects (2969) 2969
health aspects (2952) 2952
trastuzumab (2910) 2910
antineoplastic agents - therapeutic use (2786) 2786
aged, 80 and over (2662) 2662
analysis (2448) 2448
breast neoplasms - drug therapy (2410) 2410
angiogenesis inhibitors - administration & dosage (2352) 2352
double-blind (2340) 2340
safety (2241) 2241
ophthalmology (2204) 2204
tumors (2194) 2194
retrospective studies (2171) 2171
hematology (2137) 2137
efficacy (2093) 2093
proteins (2079) 2079
patients (2047) 2047
expression (2046) 2046
breast cancer (2031) 2031
medicine, research & experimental (1984) 1984
cetuximab (1945) 1945
vascular endothelial growth factor a - antagonists & inhibitors (1893) 1893
metastasis (1873) 1873
antibodies, monoclonal - pharmacology (1860) 1860
abridged index medicus (1835) 1835
clinical trials as topic (1831) 1831
follow-up studies (1770) 1770
angiogenesis inhibitors - therapeutic use (1766) 1766
endothelial growth-factor (1696) 1696
drug administration schedule (1687) 1687
adalimumab (1665) 1665
antibody (1657) 1657
medical research (1621) 1621
immunoglobulins (1593) 1593
antineoplastic combined chemotherapy protocols - adverse effects (1590) 1590
disease-free survival (1573) 1573
young adult (1561) 1561
rheumatology (1542) 1542
review (1540) 1540
infliximab (1538) 1538
trial (1536) 1536
antineoplastic agents - administration & dosage (1528) 1528
prognosis (1518) 1518
dose-response relationship, drug (1514) 1514
rituximab (1480) 1480
viral antibodies (1467) 1467
adolescent (1466) 1466
cell line, tumor (1461) 1461
risk factors (1461) 1461
antigens (1458) 1458
internal medicine (1453) 1453
vascular endothelial growth factor (1453) 1453
surgery (1440) 1440
cytokines (1425) 1425
breast neoplasms - pathology (1416) 1416
time factors (1406) 1406
transplantation (1405) 1405
disease (1399) 1399
hematology, oncology and palliative medicine (1395) 1395
ranibizumab (1392) 1392
antibodies, monoclonal - immunology (1367) 1367
colorectal neoplasms - drug therapy (1359) 1359
studies (1359) 1359
survival (1354) 1354
angiogenesis (1323) 1323
cancer therapies (1297) 1297
biotechnology & applied microbiology (1295) 1295
pharmacokinetics (1291) 1291
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (34603) 34603
Japanese (476) 476
German (286) 286
French (209) 209
Spanish (108) 108
Chinese (78) 78
Hungarian (50) 50
Russian (45) 45
Italian (37) 37
Polish (32) 32
Portuguese (32) 32
Czech (19) 19
Danish (16) 16
Romanian (10) 10
Norwegian (8) 8
Swedish (8) 8
Dutch (6) 6
Arabic (4) 4
Finnish (4) 4
Korean (3) 3
Hebrew (2) 2
Slovak (2) 2
Bosnian (1) 1
Croatian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical and biophysical research communications, ISSN 0006-291X, 2005, Volume 333, Issue 2, pp. 328 - 335
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2044 - 2053
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2010, Volume 125, Issue 6, pp. 1344 - 1353.e2
Journal Article
British journal of dermatology (1951), ISSN 0007-0963, 10/2015, Volume 173, Issue 4, pp. 930 - 939
Journal Article